ArticlePLoS neglected tropical diseases2026
Spatiotemporal differentiation of Plasmodium vivax populations in the western Greater Mekong Subregion using a 22-SNP barcode.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA high-resolution molecular tool for tracking and differentiating closely-related Plasmodium vivax populations is critically needed. This study aimed to develop and validate a novel single nucleotide polymorphism (SNP) barcode to monitor the progress of malaria elimination in the Great Mekong Subregion (GMS). METHODOLOGY/PRINCIPAL
findingsA total of 210 P. vivax clinical samples were collected across four time points in three international border areas: China-Myanmar border, Thailand-Myanmar border, and Bangladesh-Myanmar border. Parasites were genotyped at 36 SNPs using MassARRAY technology (Sequenom), with Sanger sequencing validation for low-efficiency loci. The complexity of infection (COI) was estimated via a maximum likelihood approach implemented in COIL, while genetic diversity metrics were computed in GenAIEx version 6.5. Population differentiation was assessed through molecular variance analysis, Mantel rank test, and pairwise FST estimation. Genetic structure was resolved using principal component analysis, phylogenetic analysis, and ADMIXTURE. 198 samples were successfully genotyped at 22 validated SNPs, revealing 37.9% polyclonal infections. The proportion of polyclonal infections differed significantly among the five P. vivax populations (P = 0.0001, Pearson Chi-square test, χ2 = 23.15), with 2020 CMB samples having the highest proportion (56.1%). The average COI was highest in BMB parasites (1.109 ± 0.007). The TMB 2018 samples exhibited the maximal nucleotide diversity (π = 0.342 ± 0.033) and expected heterozygosity (He = 0.325 ± 0.04). The P. vivax populations from the western GMS showed significantly reduced genetic diversity in recent years compared to earlier timepoints (0.372 ± 0.009 vs. 0.426 ± 0.009; P < 0.0001, Student's t-test). Pairwise FST values indicated moderate to high genetic differentiation (0.165 - 0.417) across nine population pairs, except for the temporally proximal CMB populations, which showed low differentiation. Structure analysis consistently resolved three discrete genetic clusters corresponding to CMB, TMB, and BMB parasite populations. CONCLUSIONS/SIGNIFICANCE: This 22-SNP barcode provides a high-resolution genotyping tool capable of differentiating P. vivax parasite infections from the western GMS. Our data demonstrate that sustained malaria control interventions drive the fragmentation of P. vivax populations into genetically distinct transmission foci, creating opportunities for elimination strategies in border hotspots.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.